Skip to main content
Clinical Trials/NCT02582567
NCT02582567
Completed
Not Applicable

Effects of Supervised Exercise During Gestation on Maternal and Foetal Health Markers. The GESTAFIT Project

Universidad de Granada1 site in 1 country140 target enrollmentOctober 1, 2015
ConditionsPregnancy

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pregnancy
Sponsor
Universidad de Granada
Enrollment
140
Locations
1
Primary Endpoint
Insulin sensitivity derived from the homeostatic model assessment for insulin resistance (HOMA-IR)
Status
Completed
Last Updated
5 months ago

Overview

Brief Summary

The main objective of this project is to assess the effects of a novel and supervised exercise intervention in overweight pregnant and their newborn.

Methods/Design: The present study is a Randomized Controlled Trial. Sixty overweight pregnant interested in participate in the intervention program will be randomly assigned to either exercise (3 sessions/week), or to usual care (control) group (30 pregnant per group). The primary outcome measures are maternal weight gain, and maternal and neonatal glycaemic profile. Secondary outcomes measure are: i) body composition; ii) dietary patterns; iii) physical fitness; iv) objectively measured physical activity and sedentary behaviour; v) sleep quality; vi) mental health, quality of life and positive health; vii) haematology and biochemical analysis; viii) oxidative stress; ix) pro- and anti-inflammatory markers; x) bone health biomarkers; xi) adiposity-related proteins expression. The data will be analysed on an intention-to-treat basis and per protocol.

Registry
clinicaltrials.gov
Start Date
October 1, 2015
End Date
July 1, 2018
Last Updated
5 months ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Virginia A. Aparicio García-Molina

PhD

Universidad de Granada

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Insulin sensitivity derived from the homeostatic model assessment for insulin resistance (HOMA-IR)

Time Frame: 34th week of gestation

Insulin sensitivity will be derived from the homeostatic model assessment for insulin resistance (HOMA-IR), which will be calculated using the formula \[fasting insulin (μIU/mL) x fasting glucose (mg/dL)\]/405.

Maternal weight gain (kg)

Time Frame: 34th week of gestation

Maternal weight gain will be defined as the weight change from baseline measurement to the last measurement

Neonatal insuline-glucose index

Time Frame: At delivery in cord blood samples

Neonatal insulin sensitivity will be assessed through the ratio glucose/insulin.

Secondary Outcomes

  • Systolic and diastolic blood pressure (mmHg)(at the 16th and 34th week of gestation)
  • Resting heart rate (bpm)(at the 16th and 34th week of gestation)
  • The Mediterranean Diet Score(at the 16th and 34th week of gestation)
  • Cardiorespiratory fitness (Vo2max)(at the 16th and 34th week of gestation)
  • Cardiorespiratory fitness (meters in the 6-min walk test)(at the 16th and 34th week of gestation)
  • Muscle strength (kg)(at the 16th and 34th week of gestation)
  • Flexibility (cm)(at the 16th and 34th week of gestation)
  • Physical activity and sedentary behaviour (in minutes)(at the 16th, 24th and 34th week of gestation)
  • Sleep behaviours (through accelerometry)(at the 16th, 24th and 34th week of gestation)
  • Pittsburgh Sleep Quality Index(at the 16th, 24th and 34th week of gestation)
  • Insomnia Symptoms Questionnaire(at the 16th, 24th and 34th week of gestation)
  • Quality of life (Short-Form Health Survey 36)(at the 16th and 34th week of gestation)
  • Epidemiological Studies-Depression Scale questionnaire(at the 16th and 34th week of gestation)
  • State Trait Anxiety Index.(at the 16th and 34th week of gestation)
  • The Detention of Restless Legs Syndrome questionnaire(at the 16th and 34th week of gestation)
  • Oswestry Disability Index score(at the 16th and 34th week of gestation)
  • Pain Visual Analogue Scale(at the 16th and 34th week of gestation)
  • 6-item Female Sexual Function Index(at the 16th and 34th week of gestation)
  • Positive health(at the 16th and 34th week of gestation)
  • Haematology(at 34th week of gestation and at delivery)
  • Lipid profile (in mother and cord blood)(at 34th week of gestation and at delivery)
  • Glycaemic profile (in mother and cord blood)(at 34th week of gestation and at delivery)
  • Total plasma antioxidant capacity (in mother and cord blood)(at 34th week of gestation and at delivery)
  • Plasma liposoluble antioxidants (in mother and cord blood)(at 34th week of gestation and at delivery)
  • Antioxidant enzymes activity (in mother and cord blood)(at 34th week of gestation and at delivery)
  • Carbonyl proteins (in mother and cord blood)(at 34th week of gestation and at delivery)
  • Oxidative damage to lipids (in mother and cord blood)(at 34th week of gestation and at delivery)
  • Oxidative damage to DNA (in mother and cord blood)(at 34th week of gestation and at delivery)
  • Pro- and anti-inflammatory signal (in mother and cord blood)(at 34th week of gestation and at delivery)
  • Bone biomarkers (in mother and cord blood)(at 34th week of gestation and at delivery)
  • Adiposity-related proteins expression (in mother and cord blood)(At delivery)
  • Anthropometry and Body Composition of the Mother and Child (Gestafitos)(4 ± 1 years after birth)
  • Blood Pressure and Resting Heart Rate of the Mother and Child (Gestafitos)(4 ± 1 years after birth)
  • Nutritional Status of the Mother and Child (Gestafitos)(4 ± 1 years after birth)
  • Physical Activity, Sedentary Behavior, and Sleep Quality of the Mother and Child(4 ± 1 years after birth)
  • Health-Related Physical Fitness of the Child: PREFIT Battery(4 ± 1 years after birth)
  • Brain Structure, Cerebral Blood Flow, and Brain Function via Structural and Functional Magnetic Resonance Imaging (Gestafitos)(4 ± 1 years after birth)
  • Cognition (Gestafitos)(4 ± 1 years after birth)
  • Academic Performance (Gestafitos)(4 ± 1 years after birth)
  • Genetic and Epigenetic Analyses (Gestafitos)(4 ± 1 years after birth)
  • Oxidative stress and antioxidant defence (Placentraining)(after placental expulsion following birth)
  • Expression of markers of biogenesis, autophagy, mitochondrial fusion-fission processes (Placentraining)(after placental expulsion following birth)
  • Trace and ultra-trace minerals (Placentraining)(after placental expulsion following birth)
  • Genomic and methylation (Placentraining)(after placental expulsion following birth)
  • Candidate gene expression and Small RNA analysis (Placentraining)(after placental expulsion following birth)
  • Targeted and untargeted metabolomics and lipidomics analyses(after placental expulsion following birth)
  • Toxics (Placentraining)(after placental expulsion following birth)
  • Inflammatory, anti-inflammatory, vasculogenesis and angiogenesis markers (Placentraining)(after placental expulsion following birth)

Study Sites (1)

Loading locations...

Similar Trials